MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGENMaster Development and License Agreement • August 9th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), dated July 6, 2017 (the “Effective Date”) between SunGen Pharma LLC, 303C College Road East, Princeton, NJ 08540, USA (SunGen) and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey, USA (“Elite”); SunGen and Elite may sometimes hereinafter be referred to as a “Party” or collectively as the “Parties”.
SECOND AMENDMENT TO THE MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGEN PHARMA, LLCMaster Development and License Agreement • August 9th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of July 24, 2017 (the “Amendment”), by and between SunGen Pharma, LLC, a limited liability company with its offices at 303C College Road East, Princeton, NJ 08540 (“SunGen”), and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), a corporation organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”), relating to that Master Development and License Agreement For Products dated August 24, 2016 and the First Amendment to the Master Development and License Agreement for Products both Between Elite Pharmaceuticals, Inc. and SunGen (together the “Agreement”);
FIRST AMENDMENT TO THE MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGEN PHARMA, LLCMaster Development and License Agreement • August 9th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of December 1, 2016 (the “Amendment”), by and between SunGen Pharma, LLC, a limited liability company with its offices at 303C College Road East, Princeton, NJ 08540 (“SunGen”), and Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), a corporation organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”), relating to that Master Development and License Agreement For Products Between Elite Pharmaceuticals, Inc. and SunGen dated August 24, 2016 (the “Agreement”);
